ResearcherShinshu UniversityActive in the last 2 years

Kentaro Umemura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1259-5438; OpenAlex author ID A5015341498. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models. Co-author DOI 10.1016/j.ebiom.2026.106137 ↗
PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-24-1095 ↗
Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-021-10848-8 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Daisuke Ban · 2 shared papers, 2025–2026 · strength 0.42
- Paper Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in p… DOI 10.1016/j.ebiom.2026.106137 ↗
- Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095 ↗
Yosuke Igarashi · 2 shared papers, 2025–2026 · strength 0.42
- Paper Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in p… DOI 10.1016/j.ebiom.2026.106137 ↗
- Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095 ↗
Yoshiaki Tanji · 2 shared papers, 2025–2026 · strength 0.42
- Paper Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in p… DOI 10.1016/j.ebiom.2026.106137 ↗
- Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095 ↗
Shinji Tanaka · 2 shared papers, 2025–2026 · strength 0.42
- Paper Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in p… DOI 10.1016/j.ebiom.2026.106137 ↗
- Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095 ↗
Yuji Soejima · 2 shared papers, 2022–2025 · strength 0.33
- Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095 ↗
- Paper Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Duct… DOI 10.1245/s10434-021-10848-8 ↗
Toru Ikegami · 1 shared paper, 2026 · strength 0.22
- Paper Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in p… DOI 10.1016/j.ebiom.2026.106137 ↗
Yuki Mochida · 1 shared paper, 2026 · strength 0.22
- Paper Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in p… DOI 10.1016/j.ebiom.2026.106137 ↗
Hiroaki Ono · 1 shared paper, 2025 · strength 0.19
- Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095 ↗
Minoru Tanabe · 1 shared paper, 2025 · strength 0.19
- Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095 ↗
Kôji Kubota · 1 shared paper, 2022 · strength 0.14
- Paper Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Duct… DOI 10.1245/s10434-021-10848-8 ↗
Hitoshi Masuo · 1 shared paper, 2022 · strength 0.14
- Paper Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Duct… DOI 10.1245/s10434-021-10848-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.